HARBIN, China, Jan. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that three of its wholly-owned subsidiaries, Harbin TDR Medical Science and Technology, Heilongjiang Tianlong Pharmaceutical, and Harbin First Bioengineering, have been granted the High-Technology Enterprise Certificate by the provincial government in Heilongjiang Province, which allows them to receive a preferential income tax rate of 15% versus the regular rate of 25%, effective January 1, 2009.
The High-Tech Enterprise Certificate is awarded to qualified enterprises by the Chinese government. Since mid-2008, provincial governments began to reassess the criteria for the High-Tech Enterprise Certificate, which include high Research and Development expenditure, and the manufacture of proprietary high technology products or services with at least 60% of total revenues for the enterprise generated through the sale of high technology products or services. With the award of the certification, China Sky One Medical will enjoy a long-term preferential income tax rate.
"We are pleased to benefit from a lower income tax rate, which will significantly have a positive effect on our financial performance," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One Medical. "We believe that the High-Tech Enterprise Certificate enhances our competitive position and validates our commitment to being an industry leader in the research and development of high technology medical products."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the ma
|SOURCE China Sky One Medical, Inc.|
Copyright©2009 PR Newswire.
All rights reserved